



Lyrica[®] (pregabalin) – First-time generic

- On July 23, 2019, Ascend Laboratories launched an [AA-rated](#) generic version of Pfizer's [Lyrica \(pregabalin\)](#) oral solution.
- Lyrica is indicated for:
 - Management of neuropathic pain associated with diabetic peripheral neuropathy
 - Management of postherpetic neuralgia
 - Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older
 - Management of fibromyalgia
 - Management of neuropathic pain associated with spinal cord injury
- Pregabalin is also available as a generic capsule and branded extended-release tablet ([Lyrica CR](#)).
 - The oral capsule carries the same indications as the oral solution.
 - Lyrica CR is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.